首页> 外文期刊>Women’s health. >Hypoactive Sexual Desire Disorder and current pharmacotherapeutic options in women.
【24h】

Hypoactive Sexual Desire Disorder and current pharmacotherapeutic options in women.

机译:女性性欲减退和当前的药物治疗选择。

获取原文
获取原文并翻译 | 示例
       

摘要

Hypoactive Sexual Desire Disorder (HSDD) is the most common female sexual dysfunction. The diagnosis of HSDD requires the existence of personal distress or interpersonal difficulties associated with low sexual desire, that cannot be explained by any other psychiatric affection and that is not exclusively due to a disease or substance. HSDD can have a serious effect on emotional wellbeing and interpersonal relationships, and it occurs in premenopausal and postmenopausal women. The Decreased Sexual Desire Screener is a shortened diagnostic method designed to help doctors who are not specialized in female sexual dysfunction to diagnose acquired HSDD in women. There is evidence that treatment with androgens or with estrogens is effective in HSDD; however, important unanswered questions still exist. Presently, new therapeutic strategies to combat HSDD are being researched, including novel methods of testosterone provision and drugs that act upon the CNS.
机译:性欲减退(HSDD)是最常见的女性性功能障碍。 HSDD的诊断需要存在与性欲低下相关的个人困扰或人际交往困难,这不能用任何其他精神病学来解释,也不仅仅是由于疾病或物质引起的。 HSDD会对情绪健康和人际关系产生严重影响,它发生在绝经前和绝经后妇女中。减少性欲筛查者是一种缩短的诊断方法,旨在帮助不专门研究女性性功能障碍的医生诊断女性获得性HSDD。有证据表明,用雄激素或雌激素治疗对HSDD有效。但是,仍然存在重要的未解决问题。当前,正在研究对抗HSDD的新治疗策略,包括提供睾丸激素的新方法和作用于CNS的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号